Regeneron’s Future Plans for its AAV Targeting Approach

This is the second part of an interview with Sven Moller-Tank, PhD. For the first part, click here.

Sven Moller-Tank, PhD
Credit: Drug Discovery & Development

In an interview with CGTLive® at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held May 13 to 17, 2025, in New Orleans, LA, Sven Moller-Tank, PhD, a senior director at Regeneron, discussed the company's poster presentations at the conference. Following up on this, CGTLive additionally asked him about future plans for the company's gene therapy efforts.

Moller-Tank pointed out that the company has pushed forward its unique approach to adeno-associated virus (AAV) targeting in the context of skeletal muscle, the central nervous system (CNS), and the peripheral nervous system, but that it plans to eventually expand beyond those areas. In addition, he spoke about his thoughts on current trends in the field of gene therapy in general.

CGTLive: Are there any future plans for Regeneron that you can discuss?

Sven Moller-Tank, PhD: My primary interest is in the targeting component. We're doing a lot of cool stuff outside of that, but I'm going to focus on the targeting. We're continuing to advance our platforms for targeting, again, the skeletal muscle, the CNS, and the peripheral nervous system, and we want to push that to a state where they're ready to go into the clinic. But also we're interested in targeting other tissues. Our entry point was muscle and CNS, we recently expanded to the peripheral nervous system, and we want to expand beyond that, where there are plenty of additional therapeutic opportunities.

Is there anything you want to add about Regeneron's work?

The only other thing is that we're really interested in combining the targeting that we've been developing for AAV, with all sorts of other modalities. So again, siRNA, lipid nanoparticles, these sorts of things. We've had initial success with our AAV, and we think there's great opportunities applying it to other modalities.

Taking a broader view, are there any trends in the industry and/or at ASGCT this year that you are paying close attention to?

Overall, the field in general has realized that gene therapy is extremely challenging and that a lot of the very early promise has been more difficult to deliver on than perhaps we had initially envisioned. But there's a lot of great work that's being done to address the current challenges. In particular, something that we've always emphasized is the need to detarget from the liver. I think the field in general has realized that that's important because of the toxicities associated with delivery to the liver or the peripheral nervous system. You see more and more that companies, especially in their capsid engineering efforts, are emphasizing more and more that this detargeting is an essential component of developing their next generation capsids.

This transcript has been edited for clarity.

Click here to view more coverage of the 2025 ASGCT Annual Meeting.